Targeting tumor microenvironment with silibinin: Promise and potential for a translational cancer chemopreventive strategy

Current Cancer Drug Targets

Volumn 13, Issue 5, 2013, Pages 486-499

  Deep, Gagan ^a,b   Agarwal, Rajesh ^a,b  

^a University of Colorado Anschutz Medical Campus   (United States)

^b UNIVERSITY OF COLORADO CANCER CENTER   (United States)

Author keywords

Angiogenesis; Chemoprevention; Inflammation; Metastasis; Silibinin; Tumor microenvironment

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; BEVACIZUMAB; BISPHOSPHONIC ACID DERIVATIVE; CATHEPSIN B; CELECOXIB; COLONY STIMULATING FACTOR 1; CYCLIN DEPENDENT KINASE INHIBITOR; DENOSUMAB; DESMIN; FIBRONECTIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MATRIX METALLOPROTEINASE; NONSTEROID ANTIINFLAMMATORY AGENT; OSTEOCLAST DIFFERENTIATION FACTOR; PROSTACYCLIN; PROTEIN P53; SEPRASE; SERINE PROTEINASE; SIBROTUZUMAB; SILIBININ; STROMAL CELL DERIVED FACTOR 1; SUNITINIB; THROMBOXANE; TRINITROBENZENESULFONIC ACID; VASCULOTROPIN; VIMENTIN; ZOLEDRONIC ACID;

ADENOMATOUS POLYP; ANGIOGENESIS; ARTICLE; BONE METASTASIS; BRAIN CANCER; BREAST CANCER; CANCER RISK; CAPILLARY DENSITY; CARCINOGENESIS; CELL MIGRATION; CHEMOPROPHYLAXIS; CLINICAL TRIAL (TOPIC); COLORECTAL CANCER; COLORECTAL CARCINOMA; DRUG TARGETING; ENDOTHELIAL PROGENITOR CELL; EPITHELIAL MESENCHYMAL TRANSITION; EXTRACELLULAR MATRIX; FIBROBLAST; GASTROINTESTINAL STROMAL TUMOR; HUMAN; INFLAMMATION; INTESTINE POLYP; KIDNEY CANCER; KIDNEY CARCINOMA; LIVER PROTECTION; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG TUMOR; METASTASIS; NEOPLASM; OSTEOBLAST; OSTEOCLASTOGENESIS; PERICYTE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; PROSTATE TUMOR; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH; TUMOR INVASION; TUMOR MICROENVIRONMENT; ULCERATIVE COLITIS;

ANIMALS; ANTIOXIDANTS; HUMANS; NEOPLASMS; SILYMARIN; TRANSLATIONAL MEDICAL RESEARCH; TUMOR MICROENVIRONMENT;

EID: 84888121025     PISSN: 15680096     EISSN: 18735576     Source Type: Journal    
DOI: 10.2174/15680096113139990041     Document Type: Article

References (130)

1. Albini, A.; Sporn, M. B. The tumour microenvironment as a target for chemoprevention. Nat. Rev. Cancer 2007, 7 (2), 139-147.
2. Bremnes, R. M.; Donnem, T.; Al-Saad, S.; Al-Shibli, K.; Andersen, S.; Sirera, R.; Camps, C.; Marinez, I.; Busund, L. T. The role of tumor stroma in cancer progression and prognosis: emphasis on carcinoma-associated fibroblasts and non-small cell lung cancer. J. Thorac. Oncol. 2011, 6 (1), 209-217.
3. Mueller, M. M.; Fusenig, N. E. Friends or foes - bipolar effects of the tumour stroma in cancer. Nat. Rev. Cancer 2004, 4 (11), 839-849.
4. Joyce, J. A. Therapeutic targeting of the tumor microenvironment. Cancer Cell 2005, 7(6), 513-520.
5. Schauer, I. G.; Sood, A. K.; Mok, S.; Liu, J. Cancer-associated fibroblasts and their putative role in potentiating the initiation and development of epithelial ovarian cancer. Neoplasia 2011, 13 (5), 393-405.
6. Allen, M.; Louise Jones, J. Jekyll and Hyde: the role of the microenvironment on the progression of cancer. J. Pathol. 2011, 223(2), 162-176.
7. Adam, B.; Toth, L.; Pasti, G.; Balazs, M.; Adany, R. Contact stimulation of fibroblasts for tenascin production by melanoma cells. Melanoma Res. 2006, 16 (5), 385-391.
8. Giannoni, E.; Bianchini, F.; Masieri, L.; Serni, S.; Torre, E.; Calorini, L.; Chiarugi, P. Reciprocal activation of prostate cancer cells and cancer-associated fibroblasts stimulates epithelial-mesenchymal transition and cancer stemness. Cancer Res. 2010, 70(17), 6945-6956.
9. Kloft, C.; Graefe, E. U.; Tanswell, P.; Scott, A. M.; Hofheinz, R.; Amelsberg, A.; Karlsson, M. O. Population pharmacokinetics of sibrotuzumab, a novel therapeutic monoclonal antibody, in cancer patients. Invest. New Drugs 2004, 22 (1), 39-52.
10. Scott, A. M.; Wiseman, G.; Welt, S.; Adjei, A.; Lee, F. T.; Hopkins, W.; Divgi, C. R.; Hanson, L. H.; Mitchell, P.; Gansen, D. N.; Larson, S. M.; Ingle, J. N.; Hoffman, E. W.; Tanswell, P.; Ritter, G.; Cohen, L. S.; Bette, P.; Arvay, L.; Amelsberg, A.; Vlock, D.; Rettig, W. J.; Old, L. J. A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Clin. Cancer Res. 2003, 9 (5), 1639-1647.
11. Hofheinz, R. D.; al-Batran, S. E.; Hartmann, F.; Hartung, G.; Jager, D.; Renner, C.; Tanswell, P.; Kunz, U.; Amelsberg, A.; Kuthan, H.; Stehle, G. Stromal antigen targeting by a humanised monoclonal antibody: an early phase II trial of sibrotuzumab in patients with metastatic colorectal cancer. Onkologie 2003, 26 (1), 44-48.
12. Bicknell, R.; Harris, A. L. Novel angiogenic signaling pathways and vascular targets. Annu.Rev. Pharmacol. Toxicol. 2004, 44 219-238.
13. Huss, W. J.; Hanrahan, C. F.; Barrios, R. J.; Simons, J. W.; Greenberg, N. M. Angiogenesis and prostate cancer: identification of a molecular progression switch. Cancer Res. 2001, 61 (6), 2736-2743.
14. Georgiou, H. D.; Namdarian, B.; Corcoran, N. M.; Costello, A. J.; Hovens, C. M. Circulating endothelial cells as biomarkers of prostate cancer. Nat. Clin. Pract. Urol. 2008, 5 (8), 445-454.
15. Carmeliet, P.; Jain, R. K. Angiogenesis in cancer and other diseases. Nature 2000, 407 (6801), 249-257.
16. Folkman, J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 1971, 285 (21), 1182-1186.
17. Folkman, J. Angiogenesis: an organizing principle for drug discovery? Nat.Rev. Drug Discov. 2007, 6 (4), 273-286.
18. Folkman, J. Angiogenesis. Annu. Rev. Med. 2006, 57, 1-18.
19. Cook, K. M.; Figg, W. D. Angiogenesis inhibitors: current strategies and future prospects. CA Cancer J. Clin. 2010, 60 (4), 222-243.
20. Samant, R. S.; Shevde, L. A. Recent advances in anti-angiogenic therapy of cancer. Oncotarget. 2011, 2 (3), 122-134.
21. Kim, E. J.; Zalupski, M. M. Systemic therapy for advanced gastrointestinal stromal tumors: beyond imatinib. J. Surg. Oncol. 2011, 104 (8), 901-906.
22. Purmonen, T. T. Cost-effectiveness of sunitinib in metastatic renal cell carcinoma. Expert Rev. Pharmacoecon Outcomes Res. 2011, 11 (4), 383-393.
23. Lin, E. Y.; Nguyen, A. V.; Russell, R. G.; Pollard, J. W. Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J. Exp. Med. 2001, 193 (6), 727-740.
24. Rogers, T. L.; Holen, I. Tumour macrophages as potential targets of bisphosphonates. J. Transl. Med. 2011, 9, 177.
25. Allavena, P.; Sica, A.; Solinas, G.; Porta, C.; Mantovani, A. The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. Crit. Rev. Oncol. Hematol. 2008, 66 (1), 1-9.
26. Sica, A.; Rubino, L.; Mancino, A.; Larghi, P.; Porta, C.; Rimoldi, M.; Solinas, G.; Locati, M.; Allavena, P.; Mantovani, A. Targeting tumour-associated macrophages. Expert Opin. Ther. Targets 2007, 11 (9), 1219-1229.
27. Bingle, L.; Brown, N. J.; Lewis, C. E. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J. Pathol. 2002, 196 (3), 254-265.
28. Langley, R. E.; Burdett, S.; Tierney, J. F.; Cafferty, F.; Parmar, M. K.; Venning, G. Aspirin and cancer: has aspirin been overlooked as an adjuvant therapy? Br. J. Cancer 2011, 105 (8), 1107-1113.
29. Meyerhardt, J. A. Beyond standard adjuvant therapy for colon cancer: role of nonstandard interventions. Semin. Oncol. 2011, 38 (4), 533-541.
30. Sporn, M. B. Perspective: The big C - for Chemoprevention. Nature 2011, 471(7339), S10-S11.
31. Miselis, N. R.; Wu, Z. J.; Van Rooijen, N.; Kane, A. B. Targeting tumor-associated macrophages in an orthotopic murine model of diffuse malignant mesothelioma. Mol. Cancer Ther. 2008, 7 (4), 788-799.
32. Veltman, J. D.; Lambers, M. E.; van Nimwegen, M.; Hendriks, R. W.; Hoogsteden, H. C.; Hegmans, J. P.; Aerts, J. G. Zoledronic acid impairs myeloid differentiation to tumour-associated macro-phages in mesothelioma. Br. J. Cancer 2010, 103 (5), 629-641.
33. Boehm, T.; Folkman, J.; Browder, T.; O'Reilly, M. S. Antiangio-genic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997, 390 (6658), 404-407.
34. Smith, M. R.; Saad, F.; Coleman, R.; Shore, N.; Fizazi, K.; Tombal, B.; Miller, K.; Sieber, P.; Karsh, L.; Damiao, R.; Tammela, T. L.; Egerdie, B.; Van Poppel, H.; Chin, J.; Morote, J.; Gomez-Veiga, F.; Borkowski, T.; Ye, Z.; Kupic, A.; Dansey, R.; Goessl, C. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet 2012, 379 (9810), 39-46.
35. Fizazi, K.; Carducci, M.; Smith, M.; Damiao, R.; Brown, J.; Karsh, L.; Milecki, P.; Shore, N.; Rader, M.; Wang, H.; Jiang, Q.; Tadros, S.; Dansey, R.; Goessl, C. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011, 377 (9768), 813-822.
36. Lyons, T. R.; O'Brien, J.; Borges, V. F.; Conklin, M. W.; Keely, P. J.; Eliceiri, K. W.; Marusyk, A.; Tan, A. C.; Schedin, P. Postpartum mammary gland involution drives progression of ductal carcinoma in situ through collagen and COX-2. Nat. Med. 2011, 17 (9), 1109-1115.
37. Lorusso, G.; Ruegg, C. The tumor microenvironment and its contribution to tumor evolution toward metastasis. Histochem. Cell Biol. 2008, 130 (6), 1091-1103.
38. Hussain, S. P.; Hofseth, L. J.; Harris, C. C. Radical causes of cancer. Nat. Rev. Cancer 2003, 3 (4), 276-285.
39. Maeda, H.; Akaike, T. Nitric oxide and oxygen radicals in infection, inflammation, and cancer. Biochemistry (Mosc) 1998, 63 (7), 854-865.
40. Brasky, T. M.; Potter, J. D.; Kristal, A. R.; Patterson, R. E.; Peters, U.; Asgari, M. M.; Thornquist, M. D.; White, E. Non-steroidal anti-inflammatory drugs and cancer incidence by sex in the VITamins And Lifestyle (VITAL) cohort. Cancer Causes Control 2012, 23 (3), 431-444.
41. Lo-Ciganic, W. H.; Zgibor, J. C.; Bunker, C. H.; Moysich, K. B.; Edwards, R. P.; Ness, R. B. Aspirin, Nonaspirin Nonsteroidal Anti-inflammatory Drugs, or Acetaminophen and Risk of Ovarian Cancer. Epidemiology 2012.
42. Tosetti, F.; Ferrari, N.; De Flora, S.; Albini, A. Angioprevention': angiogenesis is a common and key target for cancer chemopreventive agents. FASEB J. 2002, 16 (1), 2-14.
43. Singh, R. P.; Deep, G.; Chittezhath, M.; Kaur, M.; Dwyer-Nield, L. D.; Malkinson, A. M.; Agarwal, R. Effect of silibinin on the growth and progression of primary lung tumors in mice. J. Natl. Cancer Inst. 2006, 98 (12), 846-855.
44. Raina, K.; Rajamanickam, S.; Singh, R. P.; Deep, G.; Chittezhath, M.; Agarwal, R. Stage-specific inhibitory effects and associated mechanisms of silibinin on tumor progression and metastasis in transgenic adenocarcinoma of the mouse prostate model. Cancer Res. 2008, 68 (16), 6822-6830.
45. Kavitha, C. V.; Agarwal, C.; Agarwal, R.; Deep, G. Asiatic Acid inhibits pro-angiogenic effects of VEGF and human gliomas in endothelial cell culture models. PLoS One 2011, 6 (8), e22745.
46. Cavell, B. E.; Syed Alwi, S. S.; Donlevy, A.; Packham, G. Anti-angiogenic effects of dietary isothiocyanates: mechanisms of action and implications for human health. Biochem. Pharmacol. 2011, 81(3), 327-336.
47. Pfeffer, U.; Ferrari, N.; Morini, M.; Benelli, R.; Noonan, D. M.; Albini, A. Antiangiogenic activity of chemopreventive drugs. Int. J. Biol. Markers 2003, 18 (1), 70-74.
48. Longo, V. D.; Fontana, L. Calorie restriction and cancer prevention: metabolic and molecular mechanisms. Trends Pharmacol. Sci. 2010, 31(2), 89-98.
49. Fontana, L.; Klein, S. Aging, adiposity, and calorie restriction. JAMA 2007, 297(9), 986-994.
50. Hursting, S. D.; Lavigne, J. A.; Berrigan, D.; Perkins, S. N.; Barrett, J. C. Calorie restriction, aging, and cancer prevention: mechanisms of action and applicability to humans. Annu. Rev. Med. 2003, 54,131-152.
51. Jain, R. K. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat. Med. 2001, 7 (9), 987-989.
52. Fukumura, D.; Jain, R. K. Tumor microenvironment abnormalities: causes, consequences, and strategies to normalize. J.Cell Biochem. 2007, 101 (4), 937-949.
53. Goel, S.; Duda, D. G.; Xu, L.; Munn, L. L.; Boucher, Y.; Fukumura, D.; Jain, R. K. Normalization of the vasculature for treatment of cancer and other diseases. Physiol. Rev. 2011, 91 (3), 1071-1121.
54. Sorensen, A. G.; Emblem, K. E.; Polaskova, P.; Jennings, D.; Kim, H.; Ancukiewicz, M.; Wang, M.; Wen, P. Y.; Ivy, P.; Batchelor, T. T.; Jain, R. K. Increased Survival of Glioblastoma Patients Who Respond to Antiangiogenic Therapy with Elevated Blood Perfusion. Cancer Res. 2012, 72 (2), 402-407.
55. Coscia, M.; Quaglino, E.; Iezzi, M.; Curcio, C.; Pantaleoni, F.; Riganti, C.; Holen, I.; Monkkonen, H.; Boccadoro, M.; Forni, G.; Musiani, P.; Bosia, A.; Cavallo, F.; Massaia, M. Zoledronic acid repolarizes tumour-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway. J. Cell Mol. Med. 2010, 14 (12), 2803-2815.
56. Agarwal, R.; Agarwal, C.; Ichikawa, H.; Singh, R. P.; Aggarwal, B. B. Anticancer potential of silymarin: from bench to bed side. Anticancer Res. 2006, 26 (6B), 4457-4498.
57. Pradhan, S. C.; Girish, C. Hepatoprotective herbal drug, silymarin from experimental pharmacology to clinical medicine. Indian J. Med. Res. 2006, 124 (5), 491-504.
58. Deep, G.; Agarwal, R. Antimetastatic efficacy of silibinin: molecular mechanisms and therapeutic potential against cancer. Cancer Metastasis Rev. 2010, 29 (3), 447-463.
59. Singh, R. P.; Agarwal, R. A cancer chemopreventive agent silibinin, targets mitogenic and survival signaling in prostate cancer. Mutat. Res. 2004, 555 (1-2), 21-32.
60. Singh, R. P.; Agarwal, R. Mechanisms and preclinical efficacy of silibinin in preventing skin cancer. Eur. J. Cancer 2005, 41 (13), 1969-1979.
61. Singh, R. P.; Agarwal, R. Prostate cancer chemoprevention by silibinin: bench to bedside. Mol. Carcinog. 2006, 45 (6), 436-442.
62. Hanahan, D.; Folkman, J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996, 86 (3), 353-364.
63. Naumov, G. N.; Akslen, L. A.; Folkman, J. Role of angiogenesis in human tumor dormancy: animal models of the angiogenic switch. Cell Cycle 2006, 5 (16), 1779-1787.
64. Menakuru, S. R.; Brown, N. J.; Staton, C. A.; Reed, M. W. Angiogenesis in pre-malignant conditions. Br. J. Cancer 2008, 99 (12), 1961-1966.
65. Bergers, G.; Benjamin, L. E. Tumorigenesis and the angiogenic switch. Nat. Rev. Cancer 2003, 3(6), 401-410.
66. Deep, G.; Raina, K.; Singh, R. P.; Oberlies, N. H.; Kroll, D. J.; Agarwal, R. Isosilibinin inhibits advanced human prostate cancer growth in athymic nude mice: comparison with silymarin and silibinin. Int. J. Cancer 2008, 123 (12), 2750-2758.
67. Singh, R. P.; Dhanalakshmi, S.; Agarwal, C.; Agarwal, R. Silibinin strongly inhibits growth and survival of human endothelial cells via cell cycle arrest and downregulation of survivin, Akt and NF-kappaB: implications for angioprevention and antiangiogenic therapy. Oncogene 2005, 24 (7), 1188-1202.
68. Tyagi, A.; Singh, R. P.; Ramasamy, K.; Raina, K.; Redente, E. F.; Dwyer-Nield, L. D.; Radcliffe, R. A.; Malkinson, A. M.; Agarwal, R. Growth inhibition and regression of lung tumors by silibinin: modulation of angiogenesis by macrophage-associated cytokines and nuclear factor-kappaB and signal transducers and activators of transcription 3. Cancer Prev. Res. (Phila Pa) 2009, 2 (1), 74-83.
69. Rajamanickam, S.; Velmurugan, B.; Kaur, M.; Singh, R. P.; Agarwal, R. Chemoprevention of intestinal tumorigenesis in APCmin/+ mice by silibinin. Cancer Res. 2010, 70 (6), 2368-2378.
70. Singh, R. P.; Raina, K.; Deep, G.; Chan, D.; Agarwal, R. Silibinin suppresses growth of human prostate carcinoma PC-3 orthotopic xenograft via activation of extracellular signal-regulated kinase 1/2 and inhibition of signal transducers and activators of transcription signaling. Clin. Cancer Res. 2009, 15 (2), 613-621.
71. Singh, R. P.; Gu, M.; Agarwal, R. Silibinin inhibits colorectal cancer growth by inhibiting tumor cell proliferation and angiogenesis. Cancer Res. 2008, 68 (6), 2043-2050.
72. Velmurugan, B.; Singh, R. P.; Tyagi, A.; Agarwal, R. Inhibition of azoxymethane-induced colonic aberrant crypt foci formation by silibinin in male Fisher 344 rats. Cancer Prev. Res. (Phila. Pa.) 2008, 1 (5), 376-384.
73. Singh, R. P.; Raina, K.; Sharma, G.; Agarwal, R. Silibinin inhibits established prostate tumor growth, progression, invasion, and metastasis and suppresses tumor angiogenesis and epithelial-mesenchymal transition in transgenic adenocarcinoma of the mouse prostate model mice. Clin. Cancer Res. 2008, 14 (23), 7773-7780.
74. Singh, R. P.; Dhanalakshmi, S.; Tyagi, A. K.; Chan, D. C.; Agarwal, C.; Agarwal, R. Dietary feeding of silibinin inhibits advance human prostate carcinoma growth in athymic nude mice and increases plasma insulin-like growth factor-binding protein-3 levels. Cancer Res. 2002, 62 (11), 3063-3069.
75. Velmurugan, B.; Gangar, S. C.; Kaur, M.; Tyagi, A.; Deep, G.; Agarwal, R. Silibinin exerts sustained growth suppressive effect against human colon carcinoma SW480 xenograft by targeting multiple signaling molecules. Pharm. Res. 2010, 27 (10), 2085-2097.
76. Ravichandran, K.; Velmurugan, B.; Gu, M.; Singh, R. P.; Agarwal, R. Inhibitory effect of silibinin against azoxymethane-induced colon tumorigenesis in A/J mice. Clin. Cancer Res. 2010, 16(18), 4595-4606.
77. Yang, S. H.; Lin, J. K.; Huang, C. J.; Chen, W. S.; Li, S. Y.; Chiu, J. H. Silibinin inhibits angiogenesis via Flt-1, but not KDR, receptor up-regulation. J. Surg. Res. 2005, 128 (1), 140-146.
78. Ramasamy, K.; Dwyer-Nield, L. D.; Serkova, N. J.; Hasebroock, K. M.; Tyagi, A.; Raina, K.; Singh, R. P.; Malkinson, A. M.; Agarwal, R. Silibinin prevents lung tumorigenesis in wild-type but not in iNOS-/- mice: potential of real-time micro-CT in lung cancer chemoprevention studies. Clin. Cancer Res. 2011, 17 (4), 753-761.
79. Chittezhath, M.; Deep, G.; Singh, R. P.; Agarwal, C.; Agarwal, R. Silibinin inhibits cytokine-induced signaling cascades and down-regulates inducible nitric oxide synthase in human lung carcinoma A549 cells. Mol. Cancer Ther. 2008, 7 (7), 1817-1826.
80. Gu, M.; Singh, R. P.; Dhanalakshmi, S.; Agarwal, C.; Agarwal, R. Silibinin inhibits inflammatory and angiogenic attributes in photocarcinogenesis in SKH-1 hairless mice. Cancer Res. 2007, 67 (7), 3483-3491.
81. Singh, R. P.; Tyagi, A.; Sharma, G.; Mohan, S.; Agarwal, R. Oral silibinin inhibits in vivo human bladder tumor xenograft growth involving down-regulation of survivin. Clin. Cancer Res. 2008, 14(1), 300-308.
82. Yang, S. H.; Lin, J. K.; Chen, W. S.; Chiu, J. H. Anti-angiogenic effect of silymarin on colon cancer LoVo cell line. J. Surg. Res. 2003, 113 (1), 133-138.
83. Yoo, H. G.; Jung, S. N.; Hwang, Y. S.; Park, J. S.; Kim, M. H.; Jeong, M.; Ahn, S. J.; Ahn, B. W.; Shin, B. A.; Park, R. K.; Jung, Y. D. Involvement of NF-kappaB and caspases in silibinin-induced apoptosis of endothelial cells. Int. J. Mol. Med. 2004, 13 (1), 81-86.
84. Pouyssegur, J.; Dayan, F.; Mazure, N. M. Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 2006, 441 (7092), 437-443.
85. Garcia-Maceira, P.; Mateo, J. Silibinin inhibits hypoxia-inducible factor-1alpha and mTOR/p70S6K/4E-BP1 signalling pathway in human cervical and hepatoma cancer cells: implications for anticancer therapy. Oncogene 2009, 28 (3), 313-324.
86. Jung, H. J.; Park, J. W.; Lee, J. S.; Lee, S. R.; Jang, B. C.; Suh, S. I.; Suh, M. H.; Baek, W. K. Silibinin inhibits expression of HIF-1alpha through suppression of protein translation in prostate cancer cells. Biochem. Biophys. Res. Commun. 2009, 390 (1), 71-76.
87. Kim, S.; Choi, J. H.; Lim, H. I.; Lee, S. K.; Kim, W. W.; Kim, J. S.; Kim, J. H.; Choe, J. H.; Yang, J. H.; Nam, S. J.; Lee, J. E. Silibinin prevents TPA-induced MMP-9 expression and VEGF secretion by inactivation of the Raf/MEK/ERK pathway in MCF-7 human breast cancer cells. Phytomedicine 2009, 16 (6-7), 573-580.
88. Mehlen, P.; Puisieux, A. Metastasis: a question of life or death. Nat. Rev. Cancer 2006, 6 (6), 449-458.
89. Gupta, G. P.; Minn, A. J.; Kang, Y.; Siegel, P. M.; Serganova, I.; Cordon-Cardo, C.; Olshen, A. B.; Gerald, W. L.; Massague, J. Identifying site-specific metastasis genes and functions. Cold Spring Harb. Symp. Quant. Biol. 2005, 70, 149-158.
90. Nguyen, D. X.; Massague, J. Genetic determinants of cancer metastasis. Nat. Rev. Genet. 2007, 8 (5), 341-352.
91. Buijs, J. T.; van der Pluijm, G. Osteotropic cancers: from primary tumor to bone. Cancer Lett. 2009, 273 (2), 177-193.
92. Fidler, I. J. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat. Rev. Cancer 2003, 3 (6), 453-458.
93. Boudreau, N. J.; Jones, P. L. Extracellular matrix and integrin signalling: the shape of things to come. Biochem. J. 1999, 339 (Pt 3), 481-488.
94. Mitra, A. K.; Sawada, K.; Tiwari, P.; Mui, K.; Gwin, K.; Lengyel, E. Ligand-independent activation of c-Met by fibronectin and alpha(5)beta(1)-integrin regulates ovarian cancer invasion and metastasis. Oncogene 2011, 30 (13), 1566-1576.
95. Lee, M.; Park, J. J.; Lee, Y. S. Adhesion of ST6Gal I-mediated human colon cancer cells to fibronectin contributes to cell survival by integrin beta1-mediated paxillin and AKT activation. Oncol. Rep. 2010, 23 (3), 757-761.
96. Yang, Z.; Zhang, X.; Gang, H.; Li, X.; Li, Z.; Wang, T.; Han, J.; Luo, T.; Wen, F.; Wu, X. Up-regulation of gastric cancer cell invasion by Twist is accompanied by N-cadherin and fibronectin expression. Biochem. Biophys. Res. Commun. 2007, 358 (3), 925-930.
97. Mokhtari, M. J.; Motamed, N.; Shokrgozar, M. A. Evaluation of silibinin on the viability, migration and adhesion of the human prostate adenocarcinoma (PC-3) cell line. Cell Biol. Int. 2008, 32 (8), 888-892.
98. Handorean, A. M.; Yang, K.; Robbins, E. W.; Flaig, T. W.; Iczkowski, K. A. Silibinin suppresses CD44 expression in prostate cancer cells. Am. J. Transl. Res. 2009, 1 (1), 80-86.
99. Hsieh, Y. S.; Chu, S. C.; Yang, S. F.; Chen, P. N.; Liu, Y. C.; Lu, K. H. Silibinin suppresses human osteosarcoma MG-63 cell invasion by inhibiting the ERK-dependent c-Jun/AP-1 induction of MMP-2. Carcinogenesis 2007, 28 (5), 977-987.
100. Chen, P. N.; Hsieh, Y. S.; Chiou, H. L.; Chu, S. C. Silibinin inhibits cell invasion through inactivation of both PI3K-Akt and MAPK signaling pathways. Chem. Biol. Interact. 2005, 156 (2-3), 141-150.
101. Wu, K. J.; Zeng, J.; Zhu, G. D.; Zhang, L. L.; Zhang, D.; Li, L.; Fan, J. H.; Wang, X. Y.; He, D. L. Silibinin inhibits prostate cancer invasion, motility and migration by suppressing vimentin and MMP-2 expression. Acta. Pharmacol. Sin. 2009, 30 (8), 1162-1168.
102. Lee, S. O.; Jeong, Y. J.; Im, H. G.; Kim, C. H.; Chang, Y. C.; Lee, I. S. Silibinin suppresses PMA-induced MMP-9 expression by blocking the AP-1 activation via MAPK signaling pathways in MCF-7 human breast carcinoma cells. Biochem. Biophys. Res. Commun. 2007, 354 (1), 165-171.
103. Chu, S. C.; Chiou, H. L.; Chen, P. N.; Yang, S. F.; Hsieh, Y. S. Silibinin inhibits the invasion of human lung cancer cells via decreased productions of urokinase-plasminogen activator and matrix metalloproteinase-2. Mol. Carcinog. 2004, 40 (3), 143-149.
104. Chen, P. N.; Hsieh, Y. S.; Chiang, C. L.; Chiou, H. L.; Yang, S. F.; Chu, S. C. Silibinin inhibits invasion of oral cancer cells by suppressing the MAPK pathway. J. Dent. Res. 2006, 85 (3), 220-225.
105. Momeny, M.; Malehmir, M.; Zakidizaji, M.; Ghasemi, R.; Ghadimi, H.; Shokrgozar, M. A.; Emami, A. H.; Nafissi, S.; Ghavamzadeh, A.; Ghaffari, S. H. Silibinin inhibits invasive properties of human glioblastoma U87MG cells through suppression of cathepsin B and nuclear factor kappa B-mediated induction of matrix metalloproteinase 9. Anticancer Drugs, 21 (3), 252-260.
106. Christiansen, J. J.; Rajasekaran, A. K. Reassessing epithelial to mesenchymal transition as a prerequisite for carcinoma invasion and metastasis. Cancer Res. 2006, 66 (17), 8319-8326.
107. Polyak, K.; Weinberg, R. A. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat. Rev. Cancer 2009, 9(4), 265-273.
108. Deep, G.; Gangar, S. C.; Agarwal, C.; Agarwal, R. Role of E-cadherin in antimigratory and antiinvasive efficacy of silibinin in prostate cancer cells. Cancer Prev. Res. (Phila. Pa.) 2011, 4 (8), 1222-1232.
109. Tantivejkul, K.; Kalikin, L. M.; Pienta, K. J. Dynamic process of prostate cancer metastasis to bone. J. Cell Biochem. 2004, 91 (4), 706-717.
110. Msaouel, P.; Pissimissis, N.; Halapas, A.; Koutsilieris, M. Mechanisms of bone metastasis in prostate cancer: clinical implications. Best Pract. Res. Clin. Endocrinol. Metab. 2008, 22 (2), 341-355.
111. Clarke, N. W.; Hart, C. A.; Brown, M. D. Molecular mechanisms of metastasis in prostate cancer. Asian J. Androl. 2009, 11 (1), 57-67.
112. Kim, J. L.; Kang, S. W.; Kang, M. K.; Gong, J. H.; Lee, E. S.; Han, S. J.; Kang, Y. H. Osteoblastogenesis and osteoprotection enhanced by flavonolignan silibinin in osteoblasts and osteoclasts. J. Cell Biochem. 2012, 113 (1), 247-259.
113. Kim, J. H.; Kim, K.; Jin, H. M.; Song, I.; Youn, B. U.; Lee, J.; Kim, N. Silibinin inhibits osteoclast differentiation mediated by TNF family members. Mol. Cells 2009, 28 (3), 201-207.
114. Asagiri, M.; Takayanagi, H. The molecular understanding of osteoclast differentiation. Bone 2007, 40 (2), 251-264.
115. Zhao, Q.; Wang, X.; Liu, Y.; He, A.; Jia, R. NFATc1: functions in osteoclasts. Int. J. Biochem. Cell Biol. 2010, 42 (5), 576-579.
116. Provinciali, M.; Papalini, F.; Orlando, F.; Pierpaoli, S.; Donnini, A.; Morazzoni, P.; Riva, A.; Smorlesi, A. Effect of the silybin-phosphatidylcholine complex (IdB 1016) on the development of mammary tumors in HER-2/neu transgenic mice. Cancer Res. 2007, 67 (5), 2022-2029.
117. Dehmlow, C.; Murawski, N.; de Groot, H. Scavenging of reactive oxygen species and inhibition of arachidonic acid metabolism by silibinin in human cells. Life Sci. 1996, 58 (18), 1591-1600.
118. Meeran, S. M.; Katiyar, S.; Elmets, C. A.; Katiyar, S. K. Silymarin inhibits UV radiation-induced immunosuppression through augmentation of interleukin-12 in mice. Mol. Cancer Ther. 2006, 5 (7), 1660-1668.
119. Esmaily, H.; Vaziri-Bami, A.; Miroliaee, A. E.; Baeeri, M.; Abdollahi, M. The correlation between NF-kappaB inhibition and disease activity by coadministration of silibinin and ursodeoxycholic acid in experimental colitis. Fundam. Clin. Pharmacol. 2011, 25 (6), 723-733.
120. Gasparini, G.; Longo, R.; Sarmiento, R.; Morabito, A. Inhibitors of cyclo-oxygenase 2: a new class of anticancer agents? Lancet. Oncol. 2003, 4 (10), 605-615.
121. Ravichandran, K.; Tyagi, A.; Deep, G.; Agarwal, C.; Agarwal, R. Interleukin-1beta-induced iNOS expression in human lung carcinoma A549 cells: involvement of STAT and MAPK pathways. Indian J. Exp. Biol. 2011, 49 (11), 840-847.
122. Nickoloff, B. J.; Ben-Neriah, Y.; Pikarsky, E. Inflammation and cancer: is the link as simple as we think? J. Invest. Dermatol. 2005, 124 (6), x-xiv.
123. Tyagi, A.; Agarwal, C.; Dwyer-Nield, L. D.; Singh, R. P.; Malkinson, A. M.; Agarwal, R. Silibinin modulates TNF-alpha and IFN-gamma mediated signaling to regulate COX2 and iNOS expression in tumorigenic mouse lung epithelial LM2 cells. Mol.
124. Raina, K.; Agarwal, C.; Agarwal, R. Effect of silibinin in human colorectal cancer cells: Targeting the activation of NF-kappaB signaling. Mol. Carcinog. 2013, 53 (3), 195-206.
125. Dhanalakshmi, S.; Singh, R. P.; Agarwal, C.; Agarwal, R. Silibinin inhibits constitutive and TNFalpha-induced activation of NF-kappaB and sensitizes human prostate carcinoma DU145 cells to TNFalpha-induced apoptosis. Oncogene 2002, 21 (11), 1759-1767.
126. Raina, K.; Serkova, N. J.; Agarwal, R. Silibinin feeding alters the metabolic profile in TRAMP prostatic tumors: 1H-NMRS-based metabolomics study. Cancer Res. 2009, 69 (9), 3731-3735.
127. Zi, X.; Zhang, J.; Agarwal, R.; Pollak, M. Silibinin up-regulates insulin-like growth factor-binding protein 3 expression and inhibits proliferation of androgen-independent prostate cancer cells. Cancer Res. 2000, 60 (20), 5617-5620.
128. Flaig, T. W.; Glode, M.; Gustafson, D.; van Bokhoven, A.; Tao, Y.; Wilson, S.; Su, L. J.; Li, Y.; Harrison, G.; Agarwal, R.; Crawford, E. D.; Lucia, M. S.; Pollak, M. A study of high-dose oral silybin-phytosome followed by prostatectomy in patients with localized prostate cancer. Prostate 2010, 70 (8), 848-855.
129. Flaig, T. W.; Gustafson, D. L.; Su, L. J.; Zirrolli, J. A.; Crighton, F.; Harrison, G. S.; Pierson, A. S.; Agarwal, R.; Glode, L. M. A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patients. Invest. New Drugs 2007, 25 (2), 139-146.
130. Hoh, C.; Boocock, D.; Marczylo, T.; Singh, R.; Berry, D. P.; Dennison, A. R.; Hemingway, D.; Miller, A.; West, K.; Euden, S.; Garcea, G.; Farmer, P. B.; Steward, W. P.; Gescher, A. J. Pilot study of oral silibinin, a putative chemopreventive agent, in colorectal cancer patients: silibinin levels in plasma, colorectum, and liver and their pharmacodynamic consequences. Clin. Cancer Res. 2006, 12 (9), 2944-2950.